

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM435243

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
OXFORD FINANCE LLC, in its capacity as Collateral Agent and as Lender		07/14/2017	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	CORTENDO AB (PUBL)		
Street Address:	900 Northbrook Drive, Suite 200		
City:	Trevose		
State/Country:	PENNSYLVANIA		
Postal Code:	19053		
Entity Type:	Corporation: SWEDEN		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	86701398	STRONGBRIDGE BIOPHARMA	
Serial Number:	86758862	CORYNTHIA	
Serial Number:	86865505	RECORLEV	
CORRESPONDENCE DATA			
Fax Number:	4156932222		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4156932000		
Email:	crhem@cooley.com		
Correspondent Name:	Cooley LLP		
Address Line 1:	101 California Street, 5th Floor		
Address Line 4:	San Francisco, CALIFORNIA 94111		
ATTORNEY DOCKET NUMBER:	321831-132		
NAME OF SUBMITTER:	C. Rhem		
SIGNATURE:	/CR/		
DATE SIGNED:	07/14/2017		
Total Attachments: 7			
source=CRG - Release of Security Interest in USPTO Cortendo AB#page1.tif			

CH \$90.00 86701398

source=CRG - Release of Security Interest in USPTO Cortendo AB#page2.tif
source=CRG - Release of Security Interest in USPTO Cortendo AB#page3.tif
source=CRG - Release of Security Interest in USPTO Cortendo AB#page4.tif
source=CRG - Release of Security Interest in USPTO Cortendo AB#page5.tif
source=CRG - Release of Security Interest in USPTO Cortendo AB#page6.tif
source=CRG - Release of Security Interest in USPTO Cortendo AB#page7.tif

**RELEASE OF SECURITY INTEREST
IN UNITED STATES PATENTS AND TRADEMARKS**

This **RELEASE OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS** (this "Release") is made as of July 14, 2017 (this "Release") by OXFORD FINANCE LLC, in its capacity as collateral agent and as Lender, and HORIZON CREDIT II LLC, as assignee of HORIZON TECHNOLOGY FINANCE CORPORATION, as Lender (collectively, the "Grantee") in favor of CORTENDO AB (PUBL) ("Grantor"). Capitalized terms used in this Release and not otherwise defined herein have the meanings specified in the Loan Agreement (as defined below).

WHEREAS, Grantor is party to a Loan and Security Agreement, dated as of December 28, 2016 (as amended, amended and restated, supplemented or otherwise modified, the "Loan Agreement"), with Grantee pursuant to which Grantor executed and delivered to Grantee that certain Intellectual Property Security Agreement, dated as of December 28, 2016 (as amended, amended and restated, supplemented or otherwise modified, the "Intellectual Property Security Agreement");

WHEREAS, pursuant to the terms and conditions of the Loan Agreement and the Intellectual Property Security Agreement, Grantor has granted and pledged to Grantee a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of the following items or types of property being herein collectively referred to as the "Intellectual Property Collateral"), whether presently existing or hereafter arising or acquired, including, without limitation:

(i) all patents, patent applications and like protections, including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including, without limitation, the patents and patent applications referred to on Schedule A hereto (collectively, the "Patents");

(ii) any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including, without limitation, those referred to on Schedule B hereto (collectively, the "Trademarks");

(iii) any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use of infringement of the intellectual property rights identified above;

(iv) all licenses or other rights to use any of the Patents or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights; and

(v) all proceeds and products of the foregoing, including, without limitation, all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing;

WHEREAS, the Intellectual Property Security Agreement was recorded with the United States Patent and Trademark Office on December 30, 2016 at Reel/Frame 040807/0199; and

WHEREAS, Grantee has agreed to terminate and release the security interest in the Intellectual Property Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Grantee hereby terminates and releases in its entirety its security interest and lien in all of the Grantor's right, title, and interest in, to and under the Intellectual Property Collateral, and reassigns to such Grantor any and all such right, title and interest in such Intellectual Property Collateral, free and clear of all such security interest and lien.

2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantor, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest in the Intellectual Property Collateral, including, without limitation, the entire right, title and interest in and to the Intellectual Property Collateral, all renewals thereof. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee, except that Grantee has not transferred or conveyed any interest therein.

3. This Release may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Delivery by telecopier, .pdf or other electronic imaging means of an executed counterpart of a signature page to this Release shall be effective as delivery of an original executed counterpart of this Release.


4. Grantee authorizes and requests that the Commissioner for Patents and Trademarks and any other applicable government officer record this Release.

5. **THIS RELEASE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO THE PRINCIPLES OF CONFLICT OF LAWS THAT WOULD APPLY THE LAWS OF ANOTHER JURISDICTION.**

IN WITNESS WHEREOF, Grantee has caused this Release of Security Interest in United States Patents and Trademarks to be duly executed as of the date first set forth above.

GRANTEE:

OXFORD FINANCE LLC,
as collateral agent and as Lender

By: 
Name: Colette H. Featherly
Title: Senior Vice President

HORIZON CREDIT II LLC, as assignee of
HORIZON TECHNOLOGY FINANCE CORPORATION,
as Lender

By: _____
Name:
Title:

IN WITNESS WHEREOF, Grantee has caused this Release of Security Interest in United States Patents and Trademarks to be duly executed as of the date first set forth above.

GRANTEE:

OXFORD FINANCE LLC,
as collateral agent and as Lender

By: _____
Name:
Title:

HORIZON CREDIT II LLC, as assignee of
**HORIZON TECHNOLOGY FINANCE
CORPORATION,**
as Lender

By: *Gerald A. Michaud*
Name: Gerald A. Michaud
Title: President

Schedule A

PATENTS AND PATENT APPLICATIONS

1. REGISTERED PATENT

Description	Registration/Application Number	Registration/Application Date
Methods And Compositions For Treating Diabetes, Metabolic Syndrome and Other Conditions	US 15/088,539	April 4, 2016
Ketoconazole Enantiomer in Humans	US – 9.198.906	December 1, 2015
Methods And Compositions For The Treatment Of Cushing's Syndrome Using 2S,4R Ketoconazole	PCT/US15/51389	September 22, 2015
Differentiated Pharmacokinetics Of Levoketoconazole (COR-003), The Single 2S,4R-Enantiomer Of Ketoconazole, A New Investigational Drug For The Treatment Of Cushing's Syndrome	US 62/287,204 (Prov)	January 26, 2016
Pharmaceutical Compositions And Methods Of Treating Hormone-Refractory Cancers	US 62/298,772 (Prov)	February 23, 2016
Novel Functionalized 4-(Phenoxymethyl(-1,3-Dioxolane Analogs Exhibiting Cytochrome P450 Inhibition And Their Methods of Use	US – 14/760,071	July 9, 2015
Novel Functionalized 5-(Phenoxymethyl(-1,3-Dioxolane Analogs Exhibiting Cytochrome P450 Inhibition And Their Methods of Use	US – 15/024,766	March 24, 2016
Novel Cytochrome P450 Inhibitors And Their Method Of Use	US 15/021,532	March 11, 2016
Conformationally Constrained	US – 7,060,679	June 13, 2006

Backbone Cyclized Somatostatin Analogs	U.S. Patent 6051554	
Methods for Using Ketoconazole and Related Substances in Medicaments for Treatment of Type II Diabetes	US 5,849,740	December 15, 1998

Schedule B
TRADEMARKS

1. TRADEMARKS

Description	Registration/Application Number	Registration/Application Date
STRONGBRIDGE BIOPHARMA	US – 86/701,398	July 22, 2015
CORYNTHIA	US 86/758,862	September 16, 2015
RECORLEV	US – 86/865,505	January 5, 2016